Cargando…
Treatment of the antiphospholipid syndrome
The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent rec...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/ https://www.ncbi.nlm.nih.gov/pubmed/26000150 http://dx.doi.org/10.1007/s13317-013-0056-5 |
_version_ | 1782365467919253504 |
---|---|
author | Galli, Monica |
author_facet | Galli, Monica |
author_sort | Galli, Monica |
collection | PubMed |
description | The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed. |
format | Online Article Text |
id | pubmed-4389011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-43890112015-05-21 Treatment of the antiphospholipid syndrome Galli, Monica Auto Immun Highlights Review Article The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed. Springer International Publishing 2013-12-22 /pmc/articles/PMC4389011/ /pubmed/26000150 http://dx.doi.org/10.1007/s13317-013-0056-5 Text en © Springer-Verlag Italia 2013 |
spellingShingle | Review Article Galli, Monica Treatment of the antiphospholipid syndrome |
title | Treatment of the antiphospholipid syndrome |
title_full | Treatment of the antiphospholipid syndrome |
title_fullStr | Treatment of the antiphospholipid syndrome |
title_full_unstemmed | Treatment of the antiphospholipid syndrome |
title_short | Treatment of the antiphospholipid syndrome |
title_sort | treatment of the antiphospholipid syndrome |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/ https://www.ncbi.nlm.nih.gov/pubmed/26000150 http://dx.doi.org/10.1007/s13317-013-0056-5 |
work_keys_str_mv | AT gallimonica treatmentoftheantiphospholipidsyndrome |